Rheumatology

Following is a digest of pharmacogenomics journal articles pertaining to rheumatology. The SNP•its editorial team selects articles for inclusion based on clinical relevance and scientific validity. Journal articles that are most readily applicable and relevant to practicing clinicians are selected for a SNP•its Study Summary, which discusses findings and clinical implications of a pharmacogenomics study in the context of the larger evidence base.


Article Citation & LinkTypeMonthSNP•its Study Summary
Liu YP et al. Association between thiopurine s-methyltransferase polymorphisms and azathioprine-induced adverse drug reactions in patients with autoimmune diseases: a meta-analysis. PLoS One. 2015;10:e0144234.Meta-Analysis2015-12
Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause
and minimizing the risk.
Nat Rev Rheumatol. 2015 Sep 29 [Epub ahead of print].
Review2015-09
Togashi M et al. Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease. Eur J Clin Pharmacol. 2015;71:1091–7.PK2015-09
Cheng L et al. HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study. Br J Dermatol. 2015;17:555-8.Retrospective Case Control2015-08
Jani M et al. Pharmacogenetics of treatment response in psoriatic arthritis. Curr Rheumatol Rep. 2015;17:44.Review 2015-07
Jani M et al. Pharmacogenetics of treatment response in psoriatic arthritis. Curr Rheumatol Rep. 2015;17:44.Review2015-07
Saito Y et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Therap. 2015 Jun 10 [Epub ahead of print].Guidelines2015-06
Emmungil H et al. Plasma thiopurine S-methyltransferase levels and azathioprine-related adverse events in patients with Behçet’s disease. Clin Exp Rheumatol. 2015 May 1 [Epub ahead of print].Cross Sectional2015-05
Jarjour S et al. Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review. Pharmacogenomics. 2015;16:755-67.Systematic Review2015-05
Furukawa H et al. Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis. J Hum Genet. 2015 Apr 23 [Epub ahead of print].Review2015-04
Roberts RL et al. Pharmacogenetic considerations in the treatment of gout. Pharmacogenomics. 2015;16:619-29.Review2015-04
Davila L et al. Pharmacogenetics: implications for therapy in rheumatic diseases. Nat Rev Rheumatol. 2015;11:258.Review2015-03
Wen CC et al. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther. 2015; 97:518-25.GWAS2015-02
Soukup T et al. Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2015 Jan 29 [Epub ahead of print].Review2015-01
Saleh MM et al. Methylene tetrahydrofolate reductase genotypes frequencies: association with the toxicity of and response to methotrexate in rheumatoid arthritis patients. Int J Clin Pharmacol Ther. 2014 Dec 5 [Epub ahead of print].Prospective cohort2014-12
Zhang LL et al. Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis. Pharmacogenet Genomics. 2014;24:531–8.Review2014-11
Schmeling H et al. Pharmacogenetics: can genes determine treatment efficacy and safety in JIA? Nat Rev Rheumatol. 2014;10:682–90.Review2014-11
Murdaca G et al. Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept? Drug Dev Res. 2014;75 Suppl 1:S7–S10.Review2014-11
Zhang LL et al. Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis. Pharmacogenet Genomics. 2014;24:531–8.Review2014-11
McDonagh EM et al. PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. Pharmacogenet Genomics. 2014; [Epub ahead of print].Review2014-09 
Zhu H et al. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update. Pharmacogenomics.2014;15:551-66. Review2014-03 
Morgan MD et al. MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis. Pharmacogenomics. 2014;15:467-75. Meta-Analysis2014-03